BTIG Maintains a Buy on Apogee Therapeutics (APGE)

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best healthcare stocks with the highest upside. BTIG analyst Julian Harrison maintained a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE) on October 10, keeping the associated price target at $115.

The analyst based the optimistic rating on the company’s promising clinical developments, along with the potential of its APG777, especially to treat asthma, atopic dermatitis, and eosinophilic esophagitis.

According to Harrison, the expected best-in-class features associated with APG777 and the clinical data’s narrowing timelines are prominent factors suggesting considerable upside potential for Apogee Therapeutics Inc. (NASDAQ:APGE).

The firm added that the ongoing data updates and trials, when coupled with the anticipated confirmation of APG777’s safety profile and efficacy, further support the Buy rating.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a biotechnology company that offers treatments for chronic obstructive pulmonary disease (COPD), atopic dermatitis (AD), and associated inflammatory and immunology (I&I) indications.

While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.